^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Apoptosis inhibitor

21h
New P3 trial • Real-world evidence
1d
Remimazolam inhibits apoptosis of endothelial and epithelial cells by activating the PI3K/AKT pathway in acute lung injury. (PubMed, Int Immunopharmacol)
This study presents novel findings elucidating the beneficial effect of REM in ALI. This effect can be attributed to REM's ability to inhibit apoptosis by activating of the PI3K/AKT pathway in endothelial and epithelial cells. Additionally, REM targeted TSPO to regulate this pathway in endothelial cells. These results suggested a potential protective role for REM in ALI/ARDS management.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CASP7 (Caspase 7) • BAK1 (BCL2 Antagonist/Killer 1)
|
LY294002
1d
Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinoma. (PubMed, Sci Rep)
A high degree of synergism was also observed in patient-derived OAC organoids indicating the potential clinical relevance of the combination. This study demonstrates the role for dual AKT/IAP inhibition in OAC and provides a strong rationale for the further investigation of this highly efficacious combination strategy.
Journal
|
XIAP (X-Linked Inhibitor Of Apoptosis)
7d
Fenofibrate for Compensated Cirrhosis Patients with Primary Biliary Cholangitis (clinicaltrials.gov)
P2/3, N=104, Recruiting, Xijing Hospital of Digestive Diseases | Trial primary completion date: Dec 2024 --> Dec 2025
Trial primary completion date
7d
Fenofibrate Combined with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis (clinicaltrials.gov)
P3, N=150, Recruiting, Xijing Hospital of Digestive Diseases | Trial primary completion date: Dec 2024 --> Dec 2025
Trial primary completion date
13d
YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis. (PubMed, JCI Insight)
We further demonstrated that dasatinib and MYF-03-176 notably enhance the efficacy of KRAS inhibitors by reducing SRC kinase activity and TEAD activity. Overall, targeting the Hippo-YAP/TAZ pathway has the potential to overcome resistance to KRAS inhibitors.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BCL2L11 (BCL2 Like 11) • SLC7A5 (Solute Carrier Family 7 Member 5)
|
KRAS mutation • KRAS G12D
|
dasatinib
14d
ORION: AMX0035 and Progressive Supranuclear Palsy (clinicaltrials.gov)
P2/3, N=110, Active, not recruiting, Amylyx Pharmaceuticals Inc. | Recruiting --> Active, not recruiting
Enrollment closed
16d
Rhodium complex [RhLI2]I: a novel anticancer agent inducing tumor inhibition and apoptosis. (PubMed, Discov Oncol)
No long-term adverse effects on hematological or biochemical parameters or tissue levels were observed in the mice. Given these findings, this compound demonstrates significant cytotoxic effects and has the potential to serve as a promising chemotherapeutic agent, warranting further investigation at more advanced stages.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP8 (Caspase 8)
23d
The Potential Therapeutic Approach of Ursodeoxycholic Acid as a Potent Activator of ACE-2 on Cerebral Disorders Induced by γ-irradiation in Rats. (PubMed, Cell Biochem Funct)
In conclusion, UDCA treatment efficiently normalizes the above-mentioned pathological abnormalities and avoids the development of IRR-associated neurological dysfunction by upregulating the beneficial axis of RAS in the brain. Hence, ursodeoxycholic acid presents a novel option for patient care during radiotherapy.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • NOX4 (NADPH Oxidase 4)
29d
Design of a Magnetic Nanoplatform Based on CD26 Targeting and HSP90 Inhibition for Apoptosis and Ferroptosis-Mediated Elimination of Senescent Cells. (PubMed, ACS Biomater Sci Eng)
MNP@CD26@17D-mediated ferroptosis might be executed by ferritinophagy as judged by elevated levels of the ferritinophagy marker NCOA4 and a decreased pool of ferritin. As 24 h treatment with MNP@CD26@17D did not induce hemolysis in human erythrocytes in vitro, this newly designed nanoplatform could be considered as an optimal multifunctional tool to target and eliminate senescent cells of skin origin, overcoming their apoptosis resistance.
Journal
|
NCOA4 (Nuclear Receptor Coactivator 4) • DPP4 (Dipeptidyl Peptidase 4) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
1m
Colon-targeted self-assembled nanoparticles loaded with berberine double salt ameliorate ulcerative colitis by improving intestinal mucosal barrier and gut microbiota. (PubMed, Colloids Surf B Biointerfaces)
Berberine hydrochloride and ursodeoxycholic acid were combined to form a double salt (BeU), enhancing solubility and encapsulation. Remarkably, the mean colon length in the FU-PA/BeU NPs@MS group was 1.2 times longer than that in the sulfasalazine group. These dual-targeted FU-PA/BeU NPs@MS show great potential for UC treatment.
Journal
|
IL6 (Interleukin 6) • IL10 (Interleukin 10)
1m
URSTAR: Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance (clinicaltrials.gov)
P=N/A, N=128, Recruiting, First Affiliated Hospital Xi'an Jiaotong University | Not yet recruiting --> Recruiting
Enrollment open
1m
Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways. (PubMed, Cancer Biol Med)
This review emphasizes how specific gut microbiota and gut microbiota metabolites, including butyrate, propionate, and ursodeoxycholic acid, interact with oncogenic pathways to modulate anti-tumor effects...Furthermore, modulation of the gut microbiota influences glucose and lipid metabolism, thereby enhancing the response to anti-KRAS agents and addressing diarrhea induced by tyrosine kinase inhibitors. By elucidating the connection between gut microbiota and the EGFR/VEGF/KRAS pathways, this review provides valuable insights for advancing targeted cancer therapy and optimizing treatment outcomes in clinical settings.
Review • Journal
|
KRAS (KRAS proto-oncogene GTPase)
2ms
Design and synthesis of new nicotinamides as immunomodulatory VEGFR-2 inhibitors and apoptosis inducers. (PubMed, Future Med Chem)
Compound 16c boosted the level of the apoptotic caspase-3 and inhibited the level of TNF-α and IL-6 in tumor cells. Molecular docking and molecular dynamics (MD) simulations indicated the outstanding binding potential of compound 16c against VEGFR-2. Compound 16c is a good candidate for the creation of a novel antiangiogenic lead anticancer medication.
Journal • Immunomodulating
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3)
2ms
Tanshinone IIA inhibits the apoptosis process of nerve cells by upshifting SIRT1 and FOXO3α protein and regulating anti- oxidative stress molecules and inflammatory factors in Cerebral Infarction Model. (PubMed, Immunopharmacol Immunotoxicol)
In conclusion, this research elucidates that Tan IIA improves cerebral edema and neural function by elevating intracellular expression of SIRT1 and FOXO3α proteins, modulating OSM and inflammatory factors. These findings yielded robust experimental support for the potential use of Tan IIA as a therapeutic agent for CI.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • FOXO3 (Forkhead box O3) • SIRT1 (Sirtuin 1) • CRP (C-reactive protein)
2ms
Enhancing DOX efficacy against NSCLC through UDCA-mediated modulation of the TGF-β/MAPK autophagy pathways. (PubMed, Sci Rep)
Amidst this context, the present investigation delineates the synergistic potentiation of doxorubicin (DOX)-a canonical chemotherapeutic-by Ursodeoxycholic acid (UDCA), a compound with a historical pedigree in hepatobiliary medicine, now repositioned within oncological pharmacotherapy due to its dichotomous cellular modulation-affording cytoprotection to non-malignant epithelia whilst eliciting apoptotic cascades in neoplastic counterparts. The implications of this research are twofold: firstly, it offers a compelling evidence base for the clinical reevaluation of UDCA in combinatory chemotherapeutic regimens; secondly, it posits a novel mechanistic insight into the modulation of chemotherapeutic efficacy and resistance. Collectively, these insights advocate for the expedited clinical translation of UDCA-DOX synergy, potentially heralding a paradigm shift in the management of NSCLC, thereby addressing a critical lacuna in contemporary oncological therapy.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
doxorubicin hydrochloride
2ms
URSTAR: Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance (clinicaltrials.gov)
P=N/A, N=128, Not yet recruiting, First Affiliated Hospital Xi'an Jiaotong University
New trial
3ms
MicroRNA‑24 alleviates colorectal cancer progression via a rs28382740 single nucleotide polymorphism in the long noncoding region of X‑linked inhibitor of apoptosis protein. (PubMed, Oncol Lett)
The data from the present study support an inhibitory effect of miR-24s on XIAP expression. However, this inhibitory potency depends on the rs28382740 SNP genotype and may alleviate CRC progression by regulating the expression of XIAP.
Journal
|
XIAP (X-Linked Inhibitor Of Apoptosis) • MIR24-2 (MicroRNA 24-2)
|
XIAP overexpression
3ms
Microbiome-derived metabolite effects on intestinal barrier integrity and immune cell response to infection. (PubMed, Microbiology (Reading))
Here, we determined the effects of gut microbiome-derived metabolites l-tryptophan, butyrate, trimethylamine (TMA), 3-methyl-4-(trimethylammonio)butanoate (3,4-TMAB), 4-(trimethylammonio)pentanoate (4-TMAP), ursodeoxycholic acid (UDCA), glycocholic acid (GCA) and benzoate on the first line of defence in the gut...These findings reiterate the complexity of understanding microbiome effects on host physiology and underline that microbiome metabolites are crucial mediators of barrier function and the innate response to infection. Understanding these metabolites at the cellular level will allow us to move towards a better mechanistic understanding of microbiome influence over host physiology, a crucial step in advancing microbiome research.
Journal • Immune cell
|
TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
3ms
Journal
|
MMP2 (Matrix metallopeptidase 2) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9)
3ms
STAT3 and the STAT3‑regulated inhibitor of apoptosis protein survivin as potential therapeutic targets in colorectal cancer (Review). (PubMed, Biomed Rep)
In the present review, the expression, function and participation of the STAT3-survivin axis in the progression of CRC were investigated. In addition, an update on the pre-clinical and clinical trials evaluating potential treatments targeting the STAT3-survivin axis is presented.
Review • Journal
|
IL6 (Interleukin 6) • STAT3 (Signal Transducer And Activator Of Transcription 3) • BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression
3ms
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK (clinicaltrials.gov)
P2, N=54, Recruiting, Swiss Group for Clinical Cancer Research | Not yet recruiting --> Recruiting
Enrollment open
|
carboplatin • doxorubicin hydrochloride • cisplatin/vinblastine/SHAO-FA (INT230-6)
3ms
EZH2 mutation is associated with the development of visceral metastasis by enhancing proliferation and invasion and inhibiting apoptosis in breast cancer cells. (PubMed, BMC Cancer)
EZH2 mutation is associated with VM development in breast cancer patients. The EZH2K515R mutation leads to VM and a poor prognosis by enhancing proliferation and invasion and inhibiting apoptosis in breast cancer cells.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
|
BRCA2 mutation • BRCA1 mutation • EZH2 mutation • EZH2 wild-type
3ms
Ursodeoxycholic Acid Platinum(IV) Conjugates as Antiproliferative and Antimetastatic Agents: Remodel the Tumor Microenvironment through Suppressing JAK2/STAT3 Signaling. (PubMed, J Med Chem)
It displayed superior pharmacokinetic properties compared to cisplatin. The inflammatory and hypoxic TME was suppressed by downregulating COX-2, MMP9, and HIF-1α, which resulted in inhibited angiogenesis in tumors by inhibiting the HIF-1α/VEGFA axis. Additionally, the immunosuppressive TME was reversed by blocking the immune checkpoint PD-L1, further improving the density of CD3+ and CD8+ tumor-infiltrating lymphocytes, and promoting macrophage polarization from M2- to M1-type.
Journal • Metastases
|
BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CASP3 (Caspase 3) • TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9)
|
cisplatin
3ms
Study on the effects and mechanisms of Jia Wei Yin Chen Hao Tang in the treatment of hypercholanemia during pregnancy (ChiCTR2400088564)
P=N/A, N=170, Recruiting, Department of Gynecology and Obstetrics Hospital Affiliated to Zhejiang University Medical College; Women's Hospital, Medical School of Zhejiang Unive
New trial
4ms
Hypocrellin A against intrahepatic Cholangiocarcinoma via multi-target inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 signaling pathways. (PubMed, Phytomedicine)
HA, a novel natural small molecule, demonstrated promising therapeutic efficacy against ICC through its multi-target inhibitory effects on the PI3K-AKT-mTOR, MAPK, and STAT3 signaling pathways. Moreover, it exhibited notable therapeutic benefits in a primary ICC model (KRAS/P19/SB), positioning it as a novel therapeutic agent for ICC.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
4ms
Naringin alleviates gefitinib-induced hepatotoxicity through anti-oxidation, inhibition of apoptosis, and autophagy. (PubMed, Iran J Basic Med Sci)
In summary, NG alleviates GEF-induced hepatotoxicity by anti-oxidation, inhibiting cell apoptosis, and autophagy. Therefore, this study suggests the use of NG to mitigate GEF's toxicity to the liver.
Journal
|
CASP3 (Caspase 3) • CAT (Catalase)
|
gefitinib
4ms
A common CTRB misfolding variant associated with pancreatic cancer risk causes ER stress and inflammation in mice. (PubMed, bioRxiv)
The pancreas of homozygous mutant mice displays reduced chymotrypsin activity and total protein synthesis...Administration of TUDCA or sulindac partially alleviates the phenotype...- Truncated CTRB1 misfolds and accumulates in the ER; yet, mutant mice display a histologically normal pancreas at 3 months age.- CTRB1 and associated chaperones colocalize in the ER, the cytoplasm, and the nucleus of acinar cells.- Transcriptomics analysis reveals reduced activity of the acinar program and increased activity of pathways involved in ER stress, unfolded protein response, and inflammation.- Mutant mice are sensitized to pancreatic damage and do not recover properly from a mild caerulein-induced pancreatitis.- TUDCA administration partially relieves the ER stress in mutant mice.How might it impact on clinical practice in the foreseeable future?: - The new mouse model provides a tool to identify the mechanisms leading to increased pancreatic cancer risk in CTRB2 exon 6 carriers. - The findings suggest that drugs that cause ER stress relief and/or reduce inflammation might provide preventive opportunities.
Preclinical • Journal
|
AGR2 (Anterior gradient 2)
4ms
Ursodeoxycholic Acid in Patients With NAFLD - Clinical Observation (clinicaltrials.gov)
P=N/A, N=20, Recruiting, General University Hospital, Prague | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
Trial completion date • Trial primary completion date
4ms
Bile Acid Metabolism Analysis Provides Insights into Vascular Endothelial Injury in Salt-Sensitive Hypertensive Rats. (PubMed, Metabolites)
The levels of four differential bile acids (glycocholic acid, taurolithocholic acid, tauroursodeoxycholic acid, and glycolithocholic acid) significantly increased in the high-salt group. Further correlation analysis indicated that the levels of ET-1 and TNF-α were positively correlated with these differential bile acid levels. This study provides new evidence for salt-sensitive cardiovascular diseases and metabolic changes caused by a high-salt diet in rats.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
4ms
Fufang Muji Granules Ameliorate Liver Fibrosis by Reducing Oxidative Stress and Inflammation, Inhibiting Apoptosis, and Modulating Overall Metabolism. (PubMed, Metabolites)
Immunohistochemistry, quantitative reverse transcription polymerase chain reaction (RT-qPCR), and quantitative analysis also revealed that FMGs regulated taurine and hypotaurine metabolism and bile acid metabolism. These findings provide a valuable understanding of the role of FMGs in liver fibrosis management.
Journal
|
IL6 (Interleukin 6) • TGFB1 (Transforming Growth Factor Beta 1) • IL1B (Interleukin 1, beta)
4ms
Ginsenoside Rh2 Alleviate Sepsis-related Encephalopathy via Up-regulating Nrf2/HO-1 Pathway and Apoptosis Inhibition. (PubMed, Cell Biochem Biophys)
On the other hand, the GSH-Px activity and SOD level were decreased along with a decreased neural reflex score. Our investigation concluded that Rh2 treatment significantly alleviated SAE damage and inhibited LPS-induced response via up-regulation of the Nrf2/HO-1 pathway to promote anti-oxidative stress capacity and inhibit neural cell apoptosis.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta)
4ms
Mutual regulation between histone methyltransferase Suv39h1 and the Wnt/β-catenin signaling pathway promoted cell proliferation and inhibited apoptosis in bone marrow mesenchymal stem cells exposed to hydroquinone. (PubMed, Toxicology)
They both promoted cell proliferation and inhibited apoptosis in the effects of HQ on BMSCs by downregulating the expression of Cyt-C, Bax, Caspase 3, and Caspase 9 and upregulating the expression of Bcl-xl. Therefore, we concluded that Suv39h1 and the Wnt/β-catenin signaling pathway may mutually regulate each other in the effects of HQ on BMSCs in order to ameliorate the altered function of BMSCs.
Journal • Epigenetic controller
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • SUV39H1 (SUV39H1 Histone Lysine Methyltransferase)
4ms
Effect of acacetin on inhibition of apoptosis in Helicobacter pylori-infected gastric epithelial cell line. (PubMed, World J Gastrointest Oncol)
Acacetin significantly improved GES-1 cell viability and inhibited apoptosis in H. pylori-infected GES-1 cells, thereby exerting a protective effect on gastric mucosal epithelial cells.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
5ms
ORION: AMX0035 and Progressive Supranuclear Palsy (clinicaltrials.gov)
P2/3, N=110, Recruiting, Amylyx Pharmaceuticals Inc. | Phase classification: P3 --> P2/3 | N=600 --> 110 | Trial completion date: May 2027 --> Nov 2029
Phase classification • Enrollment change • Trial completion date
5ms
Phoenix: Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (clinicaltrials.gov)
P3, N=664, Active, not recruiting, Amylyx Pharmaceuticals Inc. | Trial completion date: Mar 2024 --> Jan 2026
Trial completion date
5ms
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK (clinicaltrials.gov)
P2, N=54, Not yet recruiting, Swiss Group for Clinical Cancer Research | Initiation date: Jun 2024 --> Oct 2024
Trial initiation date
|
carboplatin • doxorubicin hydrochloride • cisplatin/vinblastine/SHAO-FA (INT230-6)
5ms
Promotion of Raf-1/ASK1 complex formation by corylin inhibits cell apoptosis in myocardial ischemia/reperfusion injury. (PubMed, Int Immunopharmacol)
Mechanistically, corylin can interact with Raf-1 and promote the formation of the Raf-1/ASK1 complex, thus inhibiting cardiomyocyte apoptosis. In conclusion, our results demonstrate that corylin ameliorated cardiac dysfunction after MIR injury by reducing myocardial apoptosis.
Journal
|
ANXA5 (Annexin A5)
5ms
RNF135 Promotes Human Osteosarcoma Cell Growth and Inhibits Apoptosis by Upregulating the PI3K/AKT Pathway. (PubMed, Cancer Rep (Hoboken))
These results supported that RNF135 contributes to human OS development through PI3K/AKT-dependent mechanisms. Targeting RNF135 may provide a new therapeutic approach for treating this human malignancy.
Journal
|
CASP3 (Caspase 3) • CASP7 (Caspase 7)
5ms
SHP2 mutations promote glycolysis and inhibit apoptosis via PKM2/hnRNPK signaling in colorectal cancer. (PubMed, iScience)
Furthermore, PKM2 upregulates heterogeneous nuclear ribonucleoprotein K (hnRNPK) expression and increases CRC cell proliferation and migration/invasion via regulating hnRNPK ubiquitination. These findings provide evidence that SHP2D61Y and SHP2E76K regulate CDDP-induced apoptosis, glucose metabolism, and CRC migration/invasion through PKM2 nuclear translocation and PKM2/hnRNPK signaling.
Journal
|
HNRNPK (Heterogeneous Nuclear Ribonucleoprotein K) • PKM (Pyruvate Kinase M1/2)
5ms
Selenium deficiency exacerbates ROS/ER stress mediated pyroptosis and ferroptosis induced by bisphenol A in chickens thymus. (PubMed, J Environ Sci (China))
In vitro experiments conducted in MDCC-MSB-1 cells confirmed the results, demonstrating that the addition of antioxidant (NAC), ER stress inhibitor (TUDCA) and pyroptosis inhibitor (Vx765) alleviated oxidative stress, endoplasmic reticulum stress, pyroptosis, and ferroptosis. Overall, this study concludes that the combined effects of oxidative stress and ER stress mediate pyroptosis and ferroptosis in chicken thymus induced by BPA exposure and selenium deficiency.
Journal
|
GPX4 (Glutathione Peroxidase 4) • IL18 (Interleukin 18) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • ATF4 (Activating Transcription Factor 4) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • MT-CO2 (Mitochondrially Encoded Cytochrome C Oxidase II) • CASP1 (Caspase 1)
5ms
Trial initiation date • Surgery